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Objectives: Brimonidine tartrate is an alpha-2 agonist used for glaucoma treatment. It can lead to serious
poisoning symptoms when misused by children.
Case report: In this case report, 3 months-old male patient with severe central nervous system
depression and respiratory arrest as a result of accidentally nasal instillation of 1 cc brimonidine tartrate
that beneﬁted from mechanic ventilation and naloxone treatment was presented.
Conclusion: This case report suggested, that misuse of nasal brimonidine eye drop could result in serious
respiratory distress and central nervous system depression. Mechanical ventilation and naloxone
administration can be useful for these patients.
Copyright © 2016 The Emergency Medicine Association of Turkey. Production and hosting by Elsevier
B.V. on behalf of the Owner. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Brimonidine tartrate (Alphagan; Allergan Inc., Irvine, Calif) is an
a-2 adrenergic agonist that used for glaucoma treatment.1
Although this medicine rarely lead to poisoning, serious systemic
side effects have been observed in children following overdose or
improper use.2 Serious intoxication cases of brimonidine poison-
ings resulting from oral administration have been reported before,3
but we could not ﬁnd a case with poisoning symptoms due to nasal
administration of brimonidine in a literature search. Previous
studies have reported that giving naloxone as an antidote is not
useful in cases with severe poisoning.4,5 In this study, a three
months-old male case with brimonidine intoxication was pre-
sented. Saline was administered in nasal oriﬁce of the patient at
ﬁrst, because the problem was supposed to be a nasal congestion
resulting from inﬂuenza infection that lasting for three days.
However, respiratory failure developed and mechanical supportx: þ90 412 248 84 40.
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with three times of 0.015 mg/kg intravenous naloxone.2. Case presentation
A three month-old male child with sighs and shallow breathing
admitted to our hospital. Patient history revealed that approxi-
mately 1 cc brimonidine tartrate content eye drop had been
instilled accidentally to his nares by his grandmother to relieve
nasal congestion confusing the dropper with physiological saline
2 h ago. Physical condition of the patient was poor and there were
hypotonia, hypothermia, perioral cyanosis on his physical exami-
nation. His Glasgow coma scale was ﬁve, his pupils were miotic and
unresponsive to light. Pupillary light reﬂexes were also absent. His
heart rate was 157/min, with shallow breathing rate of 10/min.
Oxygen saturation was 85% on room air. Respiratory sounds were
barely evaluated due to hypoventilation and arterial blood pressure
was normal. Patient also had bladder globe. The other physical
examination results were normal. Complete blood count and
biochemical parameters were normal. Sinus tachycardia appeared
in the electrocardiography. Chest X-ray was normal. Nasal oxygen
and intravenous ﬂuids were given in emergency room then the
patient instantly transferred to the pediatric intensive care unit.
Patient was intubated due to severe respiratory failure and low
oxygen saturation. He was connected to a mechanical ventilator.and hosting by Elsevier B.V. on behalf of the Owner. This is an open access article
A. Gunes et al. / Turkish Journal of Emergency Medicine 16 (2016) 169e170170Naloxone was given intravenously as antidote at the dose of
0.015mg/kg every 3min consecutively 3 times until his ﬁndings get
improve. After control of breathing and heart rate the patient was
extubated with normal neurological ﬁndings compatible with his
age at the end of the hospital admission day. Then, the patient was
discharged with complete recovery without any sequel on the
fourth day of admission.
3. Discussion
Brimonidine is an a-2 selective adrenergic agonist used to treat
open-angle glaucoma or ocular hypertension and it lowers intra-
ocular pressure by reducing aqueous humor liquid production or by
increasing elimination through uveoscleral outﬂow.4 When exces-
sively instilled in the eye of children, it is carried to nasal through
nasolacrimal duct and can lead to systemic side effects by absorbing
from the nasal mucosa.6 Primary metabolism of brimonidine is in
the liver. After taken orally, it is metabolized in liver and its me-
tabolites are excreted from kidney.4 Drugs for nasal administration
directly get into systemic circulation by surviving from elimination
in liver and can cause less dose and more serious side effects.2 In
addition, because of child's blood brain barrier (BBB) is not
completely matured and brimonidine is highly lipophilic, it can
lead to severe central nervous system depressionwhen transmitted
to central nervous system.2,7 These ﬁndings can lead to fatigue,
weakness, lethargy, apnea, bradycardia, hypotension, respiratory
depression and coma, especially in children.2 In the majority of the
case reports presented in previous studies, the following ﬁndings
were determined in patients; weakness, lethargy, apnea, respira-
tory distress and recovery with symptomatic treatment.1 However,
our patient had respiratory depression, hypotension and coma. His
oxygen saturation was low. In literature, bradicardia and respira-
tory depression have rarely been reported.4
We postulated that the reason, why our patient went into coma
and his respiratory suppressed to require mechanical ventilation,
may be due to late admission to hospital and/or nasal admission of
brimonidine. In most of the studies, patients usually have admitted
to the hospital in the ﬁrst hour and signs of toxicity generally
occurred as a result of oral administration. In our study, the patient
admitted to hospital 2 h late. Children completely recover from
brimonidine intoxication in hours through symptomatic treatment.Naloxone can be helpful for patients with hypotension unrespon-
sive to adequate ﬂuid therapy and for severe cases.8 Nevertheless,
some reports show that naloxone is useless for respiratory
depression, coma and central nervous system depression in bri-
monidine intoxication.4,5 In our study, intravenous naloxone was
given following mechanical ventilation and the patient was dis-
charged with full recovery.
In conclusion, brimonidine misused in children can cause
serious side-effects. Thus, it is important to explain the details of
side effects in children to while prescribing this drug for treatment
of cataract in adults. Severity of side effects increases with nasal
use. Symptomatic treatment can be sufﬁcient in mild cases, how-
ever naloxone will be beneﬁcial for patients with central nervous
system depression.Conﬂicts of interest
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